NEW YORK (GenomeWeb News) – CombiMatrix today announced a 27 percent rise in first-quarter revenues, driven by a 158 percent jump in sales generated by its prenatal chromosomal microarray analysis testing services.

The Irvine, Calif.-based molecular diagnostics company said that total revenues for the three months ended March 31 increased to $1.6 million from $1.2 million in the first quarter of 2012. Growth in prenatal testing revenues was driven by a 124 percent increase in billable test volumes, as the firm noted when it released its preliminary results one month ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.